BioNTech Inventory vs Other Current Assets Analysis

BNTX Stock

USD 94.10 2.85 2.94%

BioNTech financial indicator trend analysis is way more than just evaluating BioNTech SE prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether BioNTech SE is a good investment. Please check the relationship between BioNTech Inventory and its Other Current Assets accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNTech SE. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.

Inventory vs Other Current Assets

Inventory vs Other Current Assets Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of BioNTech SE Inventory account and Other Current Assets. At this time, the significance of the direction appears to have strong relationship.

The correlation between BioNTech's Inventory and Other Current Assets is 0.73. Overlapping area represents the amount of variation of Inventory that can explain the historical movement of Other Current Assets in the same time period over historical financial statements of BioNTech SE, assuming nothing else is changed. The correlation between historical values of BioNTech's Inventory and Other Current Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Inventory of BioNTech SE are associated (or correlated) with its Other Current Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Current Assets has no effect on the direction of Inventory i.e., BioNTech's Inventory and Other Current Assets go up and down completely randomly.

Correlation Coefficient

0.73

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Inventory

Other Current Assets

Assets expected to be converted into cash, sold, or consumed either in one year or in the operating cycle, which are not included under standard current asset categories.

Most indicators from BioNTech's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into BioNTech SE current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNTech SE. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.

At this time, BioNTech's Selling General Administrative is fairly stable compared to the past year. Sales General And Administrative To Revenue is likely to rise to 0.21 in 2024, whereas Tax Provision is likely to drop slightly above 243 M in 2024.

BioNTech fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Good Will	Common Stock Total Equity	Short Term Investments	Non Current Liabilities Total	Inventory	Other Current Assets	Total Liab	Long Term Investments	Property Plant And Equipment Gross	Total Current Assets	Non Current Liabilities Other
Total Assets		0.76	0.82	0.85	1.0	0.98	0.62	-0.93	0.99	0.94	0.94	0.88	0.75	0.94	0.69	0.82	0.64	0.76	0.62	0.87	0.96	0.86	0.75	0.97	1.0	0.14
Short Long Term Debt Total	0.76		0.82	0.88	0.73	0.77	0.76	-0.58	0.68	0.73	0.58	0.59	0.4	0.57	0.78	0.53	0.82	0.43	0.58	0.87	0.66	0.89	0.4	0.74	0.77	0.56
Other Current Liab	0.82	0.82		0.99	0.79	0.72	0.34	-0.64	0.76	0.63	0.64	0.48	0.28	0.58	0.96	0.38	0.59	0.3	0.46	0.98	0.65	0.98	0.28	0.68	0.85	0.04
Total Current Liabilities	0.85	0.88	0.99		0.82	0.78	0.46	-0.68	0.79	0.7	0.67	0.56	0.36	0.63	0.94	0.47	0.67	0.38	0.55	1.0	0.7	1.0	0.36	0.75	0.88	0.14
Total Stockholder Equity	1.0	0.73	0.79	0.82		0.98	0.62	-0.95	1.0	0.95	0.95	0.9	0.78	0.95	0.65	0.83	0.63	0.78	0.61	0.85	0.97	0.84	0.78	0.97	0.99	0.13
Property Plant And Equipment Net	0.98	0.77	0.72	0.78	0.98		0.75	-0.93	0.98	0.98	0.94	0.94	0.82	0.96	0.58	0.88	0.69	0.82	0.64	0.8	0.98	0.8	0.82	0.99	0.97	0.27
Current Deferred Revenue	0.62	0.76	0.34	0.46	0.62	0.75		-0.53	0.6	0.8	0.55	0.79	0.72	0.63	0.27	0.79	0.69	0.74	0.62	0.46	0.67	0.49	0.72	0.77	0.59	0.74
Net Debt	-0.93	-0.58	-0.64	-0.68	-0.95	-0.93	-0.53		-0.95	-0.88	-1.0	-0.86	-0.74	-0.98	-0.44	-0.78	-0.55	-0.72	-0.49	-0.71	-0.98	-0.69	-0.74	-0.91	-0.92	-0.13
Retained Earnings	0.99	0.68	0.76	0.79	1.0	0.98	0.6	-0.95		0.95	0.96	0.91	0.8	0.97	0.61	0.85	0.59	0.8	0.62	0.82	0.97	0.81	0.8	0.97	0.99	0.09
Accounts Payable	0.94	0.73	0.63	0.7	0.95	0.98	0.8	-0.88	0.95		0.9	0.98	0.89	0.94	0.5	0.94	0.68	0.9	0.7	0.73	0.95	0.73	0.89	0.99	0.92	0.28
Cash	0.94	0.58	0.64	0.67	0.95	0.94	0.55	-1.0	0.96	0.9		0.87	0.76	0.98	0.44	0.8	0.55	0.75	0.49	0.71	0.99	0.68	0.76	0.92	0.93	0.14
Non Current Assets Total	0.88	0.59	0.48	0.56	0.9	0.94	0.79	-0.86	0.91	0.98	0.87		0.97	0.94	0.33	0.99	0.57	0.97	0.7	0.6	0.93	0.59	0.97	0.96	0.85	0.24
Non Currrent Assets Other	0.75	0.4	0.28	0.36	0.78	0.82	0.72	-0.74	0.8	0.89	0.76	0.97		0.87	0.15	0.99	0.41	1.0	0.69	0.41	0.82	0.41	1.0	0.87	0.71	0.15
Cash And Short Term Investments	0.94	0.57	0.58	0.63	0.95	0.96	0.63	-0.98	0.97	0.94	0.98	0.94	0.87		0.39	0.89	0.55	0.85	0.58	0.67	0.99	0.65	0.86	0.96	0.92	0.15
Net Receivables	0.69	0.78	0.96	0.94	0.65	0.58	0.27	-0.44	0.61	0.5	0.44	0.33	0.15	0.39		0.25	0.52	0.17	0.37	0.91	0.47	0.92	0.15	0.55	0.72	0.0
Good Will	0.82	0.53	0.38	0.47	0.83	0.88	0.79	-0.78	0.85	0.94	0.8	0.99	0.99	0.89	0.25		0.49	0.99	0.73	0.51	0.86	0.51	0.99	0.92	0.78	0.24
Common Stock Total Equity	0.64	0.82	0.59	0.67	0.63	0.69	0.69	-0.55	0.59	0.68	0.55	0.57	0.41	0.55	0.52	0.49		0.42	0.35	0.66	0.6	0.67	0.4	0.67	0.63	0.44
Short Term Investments	0.76	0.43	0.3	0.38	0.78	0.82	0.74	-0.72	0.8	0.9	0.75	0.97	1.0	0.85	0.17	0.99	0.42		0.72	0.43	0.81	0.43	1.0	0.87	0.71	0.16
Non Current Liabilities Total	0.62	0.58	0.46	0.55	0.61	0.64	0.62	-0.49	0.62	0.7	0.49	0.7	0.69	0.58	0.37	0.73	0.35	0.72		0.6	0.58	0.61	0.7	0.68	0.6	0.23
Inventory	0.87	0.87	0.98	1.0	0.85	0.8	0.46	-0.71	0.82	0.73	0.71	0.6	0.41	0.67	0.91	0.51	0.66	0.43	0.6		0.73	1.0	0.41	0.77	0.9	0.12
Other Current Assets	0.96	0.66	0.65	0.7	0.97	0.98	0.67	-0.98	0.97	0.95	0.99	0.93	0.82	0.99	0.47	0.86	0.6	0.81	0.58	0.73		0.71	0.82	0.97	0.94	0.23
Total Liab	0.86	0.89	0.98	1.0	0.84	0.8	0.49	-0.69	0.81	0.73	0.68	0.59	0.41	0.65	0.92	0.51	0.67	0.43	0.61	1.0	0.71		0.41	0.77	0.89	0.15
Long Term Investments	0.75	0.4	0.28	0.36	0.78	0.82	0.72	-0.74	0.8	0.89	0.76	0.97	1.0	0.86	0.15	0.99	0.4	1.0	0.7	0.41	0.82	0.41		0.87	0.71	0.14
Property Plant And Equipment Gross	0.97	0.74	0.68	0.75	0.97	0.99	0.77	-0.91	0.97	0.99	0.92	0.96	0.87	0.96	0.55	0.92	0.67	0.87	0.68	0.77	0.97	0.77	0.87		0.95	0.25
Total Current Assets	1.0	0.77	0.85	0.88	0.99	0.97	0.59	-0.92	0.99	0.92	0.93	0.85	0.71	0.92	0.72	0.78	0.63	0.71	0.6	0.9	0.94	0.89	0.71	0.95		0.12
Non Current Liabilities Other	0.14	0.56	0.04	0.14	0.13	0.27	0.74	-0.13	0.09	0.28	0.14	0.24	0.15	0.15	0.0	0.24	0.44	0.16	0.23	0.12	0.23	0.15	0.14	0.25	0.12

Click cells to compare fundamentals

BioNTech Account Relationship Matchups

BioNTech fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	797.6M	2.3B	15.8B	23.3B	23.0B	24.2B
Short Long Term Debt Total	68.9M	240.2M	301.5M	212.2M	219.1M	161.3M
Other Current Liab	16.4M	103.1M	3.0B	2.6B	1.3B	979.8M
Total Current Liabilities	138.1M	606.0M	3.5B	3.0B	2.1B	1.3B
Total Stockholder Equity	493.5M	1.4B	11.9B	20.1B	20.2B	21.3B
Other Liab	205.6M	97.1M	109.7M	283.9M	326.5M	166.9M
Net Tangible Assets	179.6M	406.5M	1.2B	11.7B	13.5B	14.1B
Property Plant And Equipment Net	148.1M	326.0M	520.4M	821.1M	971.6M	1.0B
Current Deferred Revenue	93.6M	391.5M	189.1M	77.1M	353.3M	371.0M
Net Debt	(450.2M)	(970.0M)	(1.4B)	(13.7B)	(11.4B)	(10.9B)
Retained Earnings	(424.8M)	(409.6M)	9.9B	18.8B	19.8B	20.8B
Accounts Payable	20.5M	102.3M	160M	204.1M	354M	371.7M
Cash	519.1M	1.2B	1.7B	13.9B	11.7B	12.2B
Non Current Assets Total	237.5M	651.7M	758.5M	1.4B	3.5B	3.7B
Non Currrent Assets Other	2K	1.0M	800K	6.5M	83.4M	87.6M
Other Assets	2.4M	168.2M	22.2M	249.2M	286.6M	300.9M
Long Term Debt	68.9M	231.0M	171.6M	176.2M	191M	116.1M
Cash And Short Term Investments	520.8M	1.3B	2.1B	14.1B	16.5B	17.4B
Net Receivables	20.2M	166.4M	12.4B	7.1B	2.3B	3.0B
Good Will	3.0M	53.7M	57.8M	61.2M	362.5M	380.6M
Common Stock Total Equity	166.8M	193.3M	232.3M	246.3M	283.3M	185.2M
Common Stock Shares Outstanding	211.5M	248.5M	259.7M	249.8M	242.7M	229.1M
Short Term Investments	1.7M	137.2M	381.6M	189.4M	4.9B	5.1B
Liabilities And Stockholders Equity	797.6M	2.3B	15.8B	23.3B	23.0B	24.2B
Non Current Liabilities Total	166.0M	340.8M	455.5M	272.9M	689.9M	378.2M
Inventory	11.7M	64.1M	502.5M	439.6M	357.7M	190.9M
Other Current Assets	1.2M	61.0M	64.9M	271.9M	280.9M	294.9M
Other Stockholder Equity	(5.5M)	1.5B	(3.8M)	(5.3M)	1.2B	1.3B
Total Liab	304.2M	946.8M	3.9B	3.2B	2.8B	1.7B
Property Plant And Equipment Gross	148.1M	326.0M	594.6M	821.1M	1.2B	1.2B
Total Current Assets	560.2M	1.7B	15.1B	21.9B	19.5B	20.5B
Accumulated Other Comprehensive Income	691.5M	25.5M	1.8B	979.3M	(984.6M)	(935.4M)
Short Term Debt	7.6M	9.1M	129.9M	36M	28.1M	32.9M
Intangible Assets	86.5M	109.8M	144.6M	158.5M	804.1M	844.3M
Common Stock	232.3M	246.3M	246.3M	248.6M	285.9M	218.0M
Property Plant Equipment	116.0M	148.1M	326.0M	520.4M	598.5M	628.4M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

DD	Dupont De Nemours
GM	General Motors
BAC	Bank of America

When determining whether BioNTech SE offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BioNTech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biontech Se Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biontech Se Stock:

How To Invest In BioNTech

Details

Is BioNTech Stock a good investment?

Details

What is BioNTech's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNTech SE. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.

You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.

Complementary Tools for BioNTech Stock analysis

When running BioNTech's price analysis, check to measure BioNTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioNTech is operating at the current time. Most of BioNTech's value examination focuses on studying past and present price action to predict the probability of BioNTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioNTech's price. Additionally, you may evaluate how the addition of BioNTech to your portfolios can decrease your overall portfolio volatility.

	Money Managers Screen money managers from public funds and ETFs managed around the world
	Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
	Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
	Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
	Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
	Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences
	Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators
	ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
	Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
	Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
	Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios
	Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings

Is BioNTech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioNTech. If investors know BioNTech will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioNTech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.80)

Earnings Share

0.5

Revenue Per Share

11.369

Quarterly Revenue Growth

(0.85)

Return On Assets

(0.01)

The market value of BioNTech SE is measured differently than its book value, which is the value of BioNTech that is recorded on the company's balance sheet. Investors also form their own opinion of BioNTech's value that differs from its market value or its book value, called intrinsic value, which is BioNTech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioNTech's market value can be influenced by many factors that don't directly affect BioNTech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between BioNTech's value and its price as these two are different measures arrived at by different means. Investors typically determine if BioNTech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioNTech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

BioNTech Inventory vs Other Current Assets Analysis

Inventory vs Other Current Assets

Inventory vs Other Current Assets Correlation Analysis

Correlation Coefficient

Inventory

Other Current Assets

BioNTech fundamental ratios Correlations

BioNTech Account Relationship Matchups

High Positive Relationship

High Negative Relationship

BioNTech fundamental ratios Accounts

Also Currently Popular

Complementary Tools for BioNTech Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Inventory	+ 1.0	Total Current Liabilities
Total Liab	+ 1.0	Total Current Liabilities
Retained Earnings	+ 1.0	Total Stockholder Equity
Short Term Investments	+ 1.0	Non Currrent Assets Other

Cash	- 1.0	Net Debt
Other Current Assets	- 0.98	Net Debt
Cash And Short Term Investments	- 0.98	Net Debt
Retained Earnings	- 0.95	Net Debt
Net Debt	- 0.95	Total Stockholder Equity
Net Debt	- 0.93	Property Plant And Equipment Net